


18-02680-E

February 22 2018

US Securities & Exchange Commission  
Office of FOIA and Privacy Act Operations  
100 F Street, NE Mail Stop 5100  
Washington, DC 20549-5100



Dear FOIA Office:

Under the Freedom of Information Act (FOIA), please send a copy of the following:

**A copy of: Exhibit 10.2 to the form 10-Q filed by Cyclacel Pharmaceuticals, Inc. on August 12, 2011**

In the event confidential treatment has not expired provide the specific date for which

confidential treatment is still in effect. I do not need a copy of the order. We authorize up to

\$61.00 in processing fees. Thank You,

**Paul D'Souza**  
Editor - Deals

**Clarivate Analytics** Friars House, 160 Blackfriars Road London, UK SE1 8EZ  
Phone: +44-2074334789  
[paul.dsouza@clarivate.com](mailto:paul.dsouza@clarivate.com)



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
STATION PLACE  
100 F STREET, NE  
WASHINGTON, DC 20549-2465

Office of FOIA Services

March 21, 2018

Mr. Paul D'Souza  
Clarivate Analytics  
160 Blackfriars Road  
London, UK SE1 8EZ

RE: Freedom of Information Act (FOIA), 5 U.S.C. § 552  
Request No. 18-02680-E

Dear Mr. D'Souza:

This letter is in response to your request, dated and received in this office on February 22, 2018, for Exhibit 10.2 to the Form 10-Q filed by Cyclacel Pharmaceuticals, Inc. on August 12, 2011.

The Commission extended confidential treatment to Exhibit 10.2 to the Form 10-Q under Rule 24b-2 of the Securities Exchange Act of 1934 through August 12, 2021. Since confidential treatment has been extended, we are providing the expiration date from the relevant CT order as requested.

If you have any questions, please contact me at [Gbenoua@sec.gov](mailto:Gbenoua@sec.gov) or (202) 551-5327. You may also contact me at [foiapa@sec.gov](mailto:foiapa@sec.gov) or (202) 551-7900. You also have the right to seek assistance from a FOIA Public Liaison, Jeffery Ovall at (202) 551-7900.

Sincerely,

*Amy Gbenou*

Amy Gbenou  
FOIA Research Specialist